397 related articles for article (PubMed ID: 17531858)
1. Glatiramer acetate: mechanisms of action in multiple sclerosis.
Ziemssen T; Schrempf W
Int Rev Neurobiol; 2007; 79():537-70. PubMed ID: 17531858
[TBL] [Abstract][Full Text] [Related]
2. Glatiramer acetate: mechanisms of action in multiple sclerosis.
Schrempf W; Ziemssen T
Autoimmun Rev; 2007 Aug; 6(7):469-75. PubMed ID: 17643935
[TBL] [Abstract][Full Text] [Related]
3. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ.
Aharoni R; Kayhan B; Eilam R; Sela M; Arnon R
Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14157-62. PubMed ID: 14614135
[TBL] [Abstract][Full Text] [Related]
4. Glatiramer acetate for the treatment of multiple sclerosis: evidence for a dual anti-inflammatory and neuroprotective role.
Liblau R
J Neurol Sci; 2009 Dec; 287 Suppl 1():S17-23. PubMed ID: 20106343
[TBL] [Abstract][Full Text] [Related]
5. Secretion of brain-derived neurotrophic factor by glatiramer acetate-reactive T-helper cell lines: Implications for multiple sclerosis therapy.
Ziemssen T; Kümpfel T; Schneider H; Klinkert WE; Neuhaus O; Hohlfeld R
J Neurol Sci; 2005 Jun; 233(1-2):109-12. PubMed ID: 15869765
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulation by the copolymer glatiramer acetate.
Arnon R; Sela M
J Mol Recognit; 2003; 16(6):412-21. PubMed ID: 14732933
[TBL] [Abstract][Full Text] [Related]
7. Do Th2 cells mediate the effects of glatiramer acetate in experimental autoimmune encephalomyelitis?
Jee Y; Liu R; Bai XF; Campagnolo DI; Shi FD; Vollmer TL
Int Immunol; 2006 Apr; 18(4):537-44. PubMed ID: 16481342
[TBL] [Abstract][Full Text] [Related]
8. Oral glatiramer acetate in experimental autoimmune encephalomyelitis: clinical and immunological studies.
Teitelbaum D; Aharoni R; Klinger E; Kreitman R; Raymond E; Malley A; Shofti R; Sela M; Arnon R
Ann N Y Acad Sci; 2004 Dec; 1029():239-49. PubMed ID: 15681762
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulation neuroprotection and remyelination - the fundamental therapeutic effects of glatiramer acetate: a critical review.
Aharoni R
J Autoimmun; 2014 Nov; 54():81-92. PubMed ID: 24934599
[TBL] [Abstract][Full Text] [Related]
10. Recent insights into the mechanism of action of glatiramer acetate.
Kala M; Miravalle A; Vollmer T
J Neuroimmunol; 2011 Jun; 235(1-2):9-17. PubMed ID: 21402415
[TBL] [Abstract][Full Text] [Related]
11. Glatiramer acetate.
Comi G; Moiola L
Neurologia; 2002 May; 17(5):244-58. PubMed ID: 12031214
[TBL] [Abstract][Full Text] [Related]
12. Glatiramer acetate reduces lymphocyte proliferation and enhances IL-5 and IL-13 production through modulation of monocyte-derived dendritic cells in multiple sclerosis.
Sanna A; Fois ML; Arru G; Huang YM; Link H; Pugliatti M; Rosati G; Sotgiu S
Clin Exp Immunol; 2006 Feb; 143(2):357-62. PubMed ID: 16412061
[TBL] [Abstract][Full Text] [Related]
13. CD4(+)CD25(+) regulatory T cells contribute to the therapeutic effects of glatiramer acetate in experimental autoimmune encephalomyelitis.
Jee Y; Piao WH; Liu R; Bai XF; Rhodes S; Rodebaugh R; Campagnolo DI; Shi FD; Vollmer TL
Clin Immunol; 2007 Oct; 125(1):34-42. PubMed ID: 17632037
[TBL] [Abstract][Full Text] [Related]
14. The use of glatiramer acetate in the treatment of multiple sclerosis.
Wolinsky JS
Adv Neurol; 2006; 98():273-92. PubMed ID: 16400839
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications.
Arnon R; Aharoni R
Proc Natl Acad Sci U S A; 2004 Oct; 101 Suppl 2(Suppl 2):14593-8. PubMed ID: 15371592
[TBL] [Abstract][Full Text] [Related]
16. Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins.
Sarchielli P; Zaffaroni M; Floridi A; Greco L; Candeliere A; Mattioni A; Tenaglia S; Di Filippo M; Calabresi P
Mult Scler; 2007 Apr; 13(3):313-31. PubMed ID: 17439900
[TBL] [Abstract][Full Text] [Related]
17. Effect of glatiramer acetate (Copaxone) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis: a longitudinal study.
Blanco Y; Moral EA; Costa M; Gómez-Choco M; Torres-Peraza JF; Alonso-Magdalena L; Alberch J; Jaraquemada D; Arbizu T; Graus F; Saiz A
Neurosci Lett; 2006 Oct; 406(3):270-5. PubMed ID: 16934924
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory potential and migratory capacities across human brain endothelial cells of distinct glatiramer acetate-reactive T cells generated in treated multiple sclerosis patients.
Kim HJ; Biernacki K; Prat A; Antel JP; Bar-Or A
Clin Immunol; 2004 Apr; 111(1):38-46. PubMed ID: 15093550
[TBL] [Abstract][Full Text] [Related]
19. Glatiramer acetate treatment does not modify the clinical course of (NZB x BXSB)F1 lupus murine model.
Borel P; Benkhoucha M; Weber MS; Zamvil SS; Santiago-Raber ML; Lalive PH
Int Immunol; 2008 Oct; 20(10):1313-9. PubMed ID: 18687587
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell, monocyte and T cell activation and response to glatiramer acetate in multiple sclerosis.
Sellebjerg F; Hesse D; Limborg S; Lund H; Søndergaard HB; Krakauer M; Sørensen PS
Mult Scler; 2013 Feb; 19(2):179-87. PubMed ID: 22653658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
